skip to search skip to navigation skip to main content

News

Astellas to Acquire Ganymed Pharmaceuticals

28th October 2016 in Mergers & Acquisitions

Tokyo and Mainz, October 28, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for…

Read Full Post

Locally manufactured Astellas Overactive Bladder (OAB) therapy to be available to Iranian patients

25th August 2016 in Local Manufacturing Launches

Partnership between Astellas Pharma and Behphar Holding realises success following last year’s agreement.   Tehran, Iran; 25 August 2016: Global leader in urology, Astellas MENA/SSA announces the availability of Vesicare in Iran, which has been locally produced by the world-class facility of Behestan Tolid. This milestone comes after the partnership agreement signed last year between…

Read Full Post

Prostate cancer mortality to incidence rate is five times greater in the MENA region than the USA1

13th March 2016 in Other activities

Astellas MENA/SSA hosts its annual Regional Oncology and Haematology Summit in Dubai Dubai, United Arab Emirates; 13 March 2016: During the Regional Oncology and Haematology Summit hosted by Astellas Middle East North & Sub Saharan Africa (MENA/SSA), a specialised briefing with regional patient groups and members of the press was held to discuss prostate cancer,…

Read Full Post

Changing Tomorrow Day – Astellas volunteers in community service projects in the region

21st February 2016 in Corporate Social Responsibility

Working with charitable organisations, Astellas Middle East, North and Sub-Saharan Africa (MENA/SSA) employees spread hope and joy through community service projects across the region through its ‘Changing Tomorrow’ initiative Dubai, United Arab Emirates; 21 February 2016: As part of its Changing Tomorrow initiative, Astellas MENA/SSA employees conducted community service activities across the region. Team members…

Read Full Post

Astellas partners with CanSurvive to raise awareness on prostate cancer in Egypt on the occasion of World Cancer

04th February 2016 in Other activities

Cairo, Egypt; February 4, 2016: Marking World Cancer Day in Egypt, Astellas MENA/SSA has announced its partnership with  CanSurvive, Egypt’s leading groups for cancer patients in the country to raise awareness on prostate cancer.  The announcement has been made at  the Cancer from Patients’ Perspective (CPP) event, which is being held on the occasion of…

Read Full Post

Changing Tomorrow Day – Astellas volunteers in community service projects in the region

27th January 2016 in Corporate Social Responsibility

Dubai, United Arab Emirates; 27 January 2016: As part of its Changing Tomorrow initiative, Astellas MENA/SSA employees conducted community service activities across the region. Team members in Algeria, Egypt, Iran, Jordan, KSA, Lebanon, and the UAE spread hope and joy to the people within the establishments they supported. Commenting on the collaborated regional community outreach,…

Read Full Post

Vesicare Launch in Algeria

16th January 2016 in Product Launches

Algiers, Algeria 10 September 2015. Astellas Middle East, North and Sub-Saharan Africa (MENA/SSA) announced that a new treatment, Solifenacin succinate, has been made available in Algeria for relieving symptoms of overactive bladder (OAB) in adults.1 This includes patients suffering from a strong, sudden urge to urinate without prior warning and having to urinate frequently.1 This…

Read Full Post

Betmiga launched in Jordan

13th January 2016 in Product Launches

Amman, Jordan; January 13, 2016: Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), today announced that a new treatment for relieving symptoms of overactive bladder (OAB) is now available in Jordan. The treatment contains the active ingredient mirabegron, providing a new and alternative treatment option to conventional antimuscarinics treatment for adult patients. OAB is…

Read Full Post

Betmiga launched in Lebanon

13th November 2015 in Product Launches

Beirut, Lebanon; November 13, 2015: Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), today announced that its latest innovative treatment for overactive bladder (OAB) is now available in Lebanon. The oral medication contains the active ingredient mirabegron, and provides a new treatment option for OAB patients. Overactive bladder (OAB) is the name of a…

Read Full Post

Local Manufacturing Partnership launched in Iran

29th October 2015 in Local Manufacturing Launches

Tehran, Iran; 29 October 2015: The Ministry of Health and Medical Education in Iran has recently welcomed the three-way partnership agreement between itself, Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), and Behestan Group for the manufacturing of urology and transplantation pharmaceutical products. The existing manufacturing plant, owned by Behestan Tolid, will receive a…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2019 Astellas Pharma